IL6-174G > C genetic polymorphism influences antidepressant treatment outcome

• Autor(a) principal: Carvalho, Serafim
• Data de Publicação: 2016
• Outros Autores: Santos, Marlene, Lima, Luís, Mota-Pereira, Jorge, Pimentel, Paulo, Maia, Dulce, Correia, Diana, Gomes, Sofia, Cruz, Agostinho, Medeiros, Rui
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.22/9333
• topic: IL6; Genetic polymorphisms; Antidepressants; Treatment resistant depression

Background: Major depressive disorder is a condition associated with dysregulated cytokine levels; among these, IL6. Furthermore, genetic variations within cytokine genes have been proposed to predict antidepressant treatment outcome. Objectives: This study aims to evaluate the role of IL6-174G > C and IL6R D358A A > C functional poly-morphisms in antidepressant treatment phenotypes, specifically remission, relapse, and treatment resistant depression (TRD). Methods: The referred polymorphisms were genotyped in 80 MDD patients followed at Hospital Magalh~aes Lemos, Portugal, within a period of 27 months. Results: It was found that patients carrying IL6-174 GC genotype present a protection towards the development of TRD (OR ¼ 0.242; 95% CI ¼ 0.068–0.869; p ¼ .038), when compared with GG genotype. Additionally, carriers of IL6-174 CC genotype remit earlier than patients with IL6-174 GG/GC genotypes, with a median time to remission of 6 weeks for CC carriers and 15 weeks for GG or GC carriers (p ¼ .030, Log-rank test). No association was found between IL6R D358A genetic polymorphism and any of the treatment phenotypes evaluated. Conclusions: The IL6-174G > C polymorphism influences antidepressant treatment outcome in this sub-set of MDD patients, providing a putative mechanistic link for the dysregulated IL-6 levels described in the literature in patients with TRD.